Targeted Elimination of G Proteins and Arrestins Defines Their Specific Contributions to Both Intensity and Duration of G Protein-coupled Receptor Signaling*

G protein-coupled receptors (GPCRs) can initiate intracellular signaling cascades by coupling to an array of heterotrimeric G proteins and arrestin adaptor proteins. Understanding the contribution of each of these coupling options to GPCR signaling has been hampered by a paucity of tools to selectively perturb receptor function. Here we employ CRISPR/Cas9 genome editing to eliminate selected G proteins (Gαq and Gα11) or arrestin2 and arrestin3 from HEK293 cells together with the elimination of receptor phosphorylation sites to define the relative contribution of G proteins, arrestins, and receptor phosphorylation to the signaling outcomes of the free fatty acid receptor 4 (FFA4). A lack of FFA4-mediated elevation of intracellular Ca2+ in Gαq/Gα11-null cells and agonist-mediated receptor internalization in arrestin2/3-null cells confirmed previously reported canonical signaling features of this receptor, thereby validating the genome-edited HEK293 cells. FFA4-mediated ERK1/2 activation was totally dependent on Gq/11 but intriguingly was substantially enhanced for FFA4 receptors lacking sites of regulated phosphorylation. This was not due to a simple lack of desensitization of Gq/11 signaling because the Gq/11-dependent calcium response was desensitized by both receptor phosphorylation and arrestin-dependent mechanisms, whereas a substantially enhanced ERK1/2 response was only observed for receptors lacking phosphorylation sites and not in arrestin2/3-null cells. In conclusion, we validate CRISPR/Cas9 engineered HEK293 cells lacking Gq/11 or arrestin2/3 as systems for GPCR signaling research and employ these cells to reveal a previously unappreciated interplay of signaling pathways where receptor phosphorylation can impact on ERK1/2 signaling through a mechanism that is likely independent of arrestins.

[1]  B. Hudson,et al.  Complex Pharmacology of Free Fatty Acid Receptors. , 2017, Chemical reviews.

[2]  B. Hudson,et al.  Syddansk Universitet Complex Pharmacology of Free Fatty Acid Receptors , 2017 .

[3]  Wen-long Huang,et al.  Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development , 2016, Expert opinion on investigational drugs.

[4]  Ashley M. Miller,et al.  Distinct Phosphorylation Clusters Determine the Signaling Outcome of Free Fatty Acid Receptor 4/G Protein–Coupled Receptor 120 , 2016, Molecular Pharmacology.

[5]  G. Lin,et al.  Potential pitfalls of CRISPR/Cas9‐mediated genome editing , 2016, The FEBS journal.

[6]  S. Nuber,et al.  β-Arrestin biosensors reveal a rapid, receptor-dependent activation/deactivation cycle , 2016, Nature.

[7]  S. Rajagopal,et al.  The β-Arrestins: Multifunctional Regulators of G Protein-coupled Receptors* , 2016, The Journal of Biological Chemistry.

[8]  A. Tobin,et al.  An Antibody Biosensor Establishes the Activation of the M1 Muscarinic Acetylcholine Receptor during Learning and Memory*♦ , 2016, The Journal of Biological Chemistry.

[9]  H. Dohlman,et al.  The experimental power of FR900359 to study Gq-regulated biological processes , 2015, Nature Communications.

[10]  A. Shukla,et al.  Emerging Functional Divergence of β-Arrestin Isoforms in GPCR Function , 2015, Trends in Endocrinology & Metabolism.

[11]  C. Chavkin,et al.  Mu opioid receptor stimulation activates c-Jun N-terminal kinase 2 by distinct arrestin-dependent and independent mechanisms. , 2015, Cellular signalling.

[12]  B. Hudson,et al.  Characterizing pharmacological ligands to study the long‐chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4 , 2015, British journal of pharmacology.

[13]  V. Gurevich,et al.  Arrestins: Critical Players in Trafficking of Many GPCRs. , 2015, Progress in molecular biology and translational science.

[14]  F. Zhang,et al.  CRISPR/Cas9 for genome editing: progress, implications and challenges. , 2014, Human molecular genetics.

[15]  B. Hudson,et al.  The Molecular Basis of Ligand Interaction at Free Fatty Acid Receptor 4 (FFA4/GPR120)* , 2014, The Journal of Biological Chemistry.

[16]  B. Hudson,et al.  Concomitant Action of Structural Elements and Receptor Phosphorylation Determines Arrestin-3 Interaction with the Free Fatty Acid Receptor FFA4* , 2014, The Journal of Biological Chemistry.

[17]  L. Bohn,et al.  Functional selectivity of GPCR signaling in animals. , 2014, Current opinion in cell biology.

[18]  N. Morgan,et al.  GPR120 (FFAR4) is preferentially expressed in pancreatic delta cells and regulates somatostatin secretion from murine islets of Langerhans , 2014, Diabetologia.

[19]  Ilya Senatorov,et al.  Mechanisms of homologous and heterologous phosphorylation of FFA receptor 4 (GPR120): GRK6 and PKC mediate phosphorylation of Thr³⁴⁷, Ser³⁵⁰, and Ser³⁵⁷ in the C-terminal tail. , 2014, Biochemical pharmacology.

[20]  G. Schulte,et al.  β-Arrestin Promotes Wnt-induced Low Density Lipoprotein Receptor-related Protein 6 (Lrp6) Phosphorylation via Increased Membrane Recruitment of Amer1 Protein* , 2013, The Journal of Biological Chemistry.

[21]  B. Hudson,et al.  The Pharmacology of TUG-891, a Potent and Selective Agonist of the Free Fatty Acid Receptor 4 (FFA4/GPR120), Demonstrates Both Potential Opportunity and Possible Challenges to Therapeutic Agonism , 2013, Molecular Pharmacology.

[22]  R. Lefkowitz,et al.  A brief history of G-protein coupled receptors (Nobel Lecture). , 2013, Angewandte Chemie.

[23]  John T. Williams,et al.  Increased Agonist Affinity at the μ-Opioid Receptor Induced by Prolonged Agonist Exposure , 2013, The Journal of Neuroscience.

[24]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[25]  B. Hudson,et al.  Discovery of a potent and selective GPR120 agonist. , 2012, Journal of medicinal chemistry.

[26]  K. Dalby,et al.  The Effect of Arrestin Conformation on the Recruitment of c-Raf1, MEK1, and ERK1/2 Activation , 2011, PloS one.

[27]  V. Gurevich,et al.  A single mutation in arrestin-2 prevents ERK1/2 activation by reducing c-Raf1 binding. , 2011, Biochemistry.

[28]  H. Subramanian,et al.  Distinct and Shared Roles of β-Arrestin-1 and β-Arrestin-2 on the Regulation of C3a Receptor Signaling in Human Mast Cells , 2011, PloS one.

[29]  T. Hakoshima,et al.  Structural basis for the specific inhibition of heterotrimeric Gq protein by a small molecule , 2010, Proceedings of the National Academy of Sciences.

[30]  L. Luttrell,et al.  Beyond Desensitization: Physiological Relevance of Arrestin-Dependent Signaling , 2010, Pharmacological Reviews.

[31]  L. Bohn,et al.  Physiological and pharmacological implications of beta-arrestin regulation. , 2009, Pharmacology & therapeutics.

[32]  Leigh A. Stoddart,et al.  Conserved Polar Residues in Transmembrane Domains V, VI, and VII of Free Fatty Acid Receptor 2 and Free Fatty Acid Receptor 3 Are Required for the Binding and Function of Short Chain Fatty Acids* , 2008, Journal of Biological Chemistry.

[33]  Jeffrey L. Benovic,et al.  M3 Muscarinic Acetylcholine Receptor-Mediated Signaling Is Regulated by Distinct Mechanisms , 2008, Molecular Pharmacology.

[34]  H. Kovacic,et al.  G␣(q/11)-coupled P2y 2 Nucleotide Receptor Inhibits Human Keratinocyte Spreading and Migration , 2022 .

[35]  Pascale G. Charest,et al.  The V2 vasopressin receptor stimulates ERK1/2 activity independently of heterotrimeric G protein signalling. , 2007, Cellular signalling.

[36]  G. Milligan,et al.  Up-regulation of the Angiotensin II Type 1 Receptor by the MAS Proto-oncogene Is Due to Constitutive Activation of Gq/G11 by MAS* , 2006, Journal of Biological Chemistry.

[37]  R. Lefkowitz,et al.  Distinct β-Arrestin- and G Protein-dependent Pathways for Parathyroid Hormone Receptor-stimulated ERK1/2 Activation* , 2006, Journal of Biological Chemistry.

[38]  G. Milligan,et al.  Heterotrimeric G‐proteins: a short history , 2006, British journal of pharmacology.

[39]  Olivier Lichtarge,et al.  β-Arrestin-dependent, G Protein-independent ERK1/2 Activation by the β2 Adrenergic Receptor* , 2006, Journal of Biological Chemistry.

[40]  Shelagh Wilson,et al.  The sustainability of interactions between the orexin-1 receptor and beta-arrestin-2 is defined by a single C-terminal cluster of hydroxy amino acids and modulates the kinetics of ERK MAPK regulation. , 2005, The Biochemical journal.

[41]  M. Taniguchi,et al.  A Novel Gαq/11-selective Inhibitor* , 2004, Journal of Biological Chemistry.

[42]  R. Lefkowitz,et al.  Desensitization, internalization, and signaling functions of β-arrestins demonstrated by RNA interference , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  P. M. Hinkle,et al.  Signal Transduction and Hormone-dependent Internalization of the Thyrotropin-releasing Hormone Receptor in Cells Lacking Gq and G11 * , 1999, The Journal of Biological Chemistry.

[44]  Melvin I. Simon,et al.  Members of the Gq alpha subunit gene family activate phospholipase C beta isozymes. , 1992, The Journal of biological chemistry.